BJDX (BJDX) Stock News & Analysis

Bluejay Diagnostics rallied in premarket trade Tuesday after saying it will partner with Argonaut Manufacturing Services on U.S. production for its Symphony near-patient test system. Shares were up 148.4% at $5.39 at 8:43 a.m. EDT, according to StockAnalysis, after closing Monday much lower. Benzinga had BJDX quoted at $6.79, up 212.9%.

Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com.